Climb BioNASDAQ: CLYM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Website:

http://eliemtx.com

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$262.88 M
-55%vs. 3y high
57%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

1.18
-58%vs. 3y high
44%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Wed, 30 Oct 2024 13:30:00 GMT
$3.92-$0.12(-2.97%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$1.81-

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--$54.89 M

Analysts recommendations

Total assets

Total liabilities

$226.02 M$3.74 M

Institutional Ownership

Included in screeners

No data

Similar companies

Eliem Therapeutics logo

Eliem Therapeutics (ELYM)

Vanda Pharmaceuticals logo

Vanda Pharmaceuticals (VNDA)

Sight Sciences logo

Sight Sciences (SGHT)

Acrivon Therapeutics Common Stock (ACRV)

Sera Prognostics logo

Sera Prognostics (SERA)

Accolade logo

Accolade (ACCD)

Personalis logo

Personalis (PSNL)

AVITA Medical logo

AVITA Medical (RCEL)

CLYM Latest News

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
globenewswire.com15 October 2024 Sentiment: POSITIVE

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
globenewswire.com11 October 2024 Sentiment: POSITIVE

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

What type of business is Climb Bio?

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

What sector is Climb Bio in?

Climb Bio is in the Healthcare sector

What industry is Climb Bio in?

Climb Bio is in the Biotechnology industry

What country is Climb Bio from?

Climb Bio is headquartered in United States

What is Climb Bio website?

https://eliemtx.com

Is Climb Bio in the S&P 500?

No, Climb Bio is not included in the S&P 500 index

Is Climb Bio in the NASDAQ 100?

No, Climb Bio is not included in the NASDAQ 100 index

Is Climb Bio in the Dow Jones?

No, Climb Bio is not included in the Dow Jones index

When was Climb Bio the previous earnings report?

No data

When does Climb Bio earnings report?

The next expected earnings date for Climb Bio is 14 November 2024